Neuropace Stock Analysis
| NPCE Stock | USD 16.23 0.48 2.87% |
Neuropace holds a debt-to-equity ratio of 1.08. Neuropace's financial risk is the risk to Neuropace stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Neuropace's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Neuropace's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Neuropace Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Neuropace's stakeholders.
For most companies, including Neuropace, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Neuropace, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Neuropace's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Neuropace's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Neuropace is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Neuropace to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Neuropace is said to be less leveraged. If creditors hold a majority of Neuropace's assets, the Company is said to be highly leveraged.
Neuropace is undervalued with Real Value of 17.47 and Hype Value of 16.23. The main objective of Neuropace stock analysis is to determine its intrinsic value, which is an estimate of what Neuropace is worth, separate from its market price. There are two main types of Neuropace's stock analysis: fundamental analysis and technical analysis.
The Neuropace stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Neuropace's ongoing operational relationships across important fundamental and technical indicators.
Neuropace | Build AI portfolio with Neuropace Stock |
Neuropace Stock Analysis Notes
About 93.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.75. Neuropace had not issued any dividends in recent years. NeuroPace, Inc. operates as a medical device company in the United States. The company was incorporated in 1997 and is headquartered in Mountain View, California. Neuropace operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 187 people. To find out more about Neuropace contact Michael Favet at 650 237 2700 or learn more at https://www.neuropace.com.Neuropace Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Neuropace's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Neuropace or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Neuropace is way too risky over 90 days horizon | |
| Neuropace appears to be risky and price may revert if volatility continues | |
| Neuropace has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 79.91 M. Net Loss for the year was (27.14 M) with profit before overhead, payroll, taxes, and interest of 72.83 M. | |
| Neuropace currently holds about 92.41 M in cash with (17.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72. | |
| Over 93.0% of the company shares are owned by institutional investors |
Neuropace Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 556.57 M.Neuropace Profitablity
The company has Profit Margin (PM) of (0.25) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.1) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.1.Technical Drivers
As of the 26th of January, Neuropace secures the Mean Deviation of 3.16, risk adjusted performance of 0.1142, and Downside Deviation of 2.69. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neuropace, as well as the relationship between them. Please verify Neuropace value at risk, as well as the relationship between the semi variance and kurtosis to decide if Neuropace is priced some-what accurately, providing market reflects its recent price of 16.23 per share. Given that Neuropace has jensen alpha of 0.6745, we recommend you to check Neuropace's last-minute market performance to make sure the company can sustain itself at a future point.Neuropace Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Neuropace middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Neuropace. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Neuropace Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neuropace insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neuropace's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Neuropace insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Neuropace Outstanding Bonds
Neuropace issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Neuropace uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Neuropace bonds can be classified according to their maturity, which is the date when Neuropace has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Neuropace Predictive Daily Indicators
Neuropace intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Neuropace stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 2705.83 | |||
| Daily Balance Of Power | (0.96) | |||
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 16.46 | |||
| Day Typical Price | 16.38 | |||
| Price Action Indicator | (0.47) | |||
| Period Momentum Indicator | (0.48) | |||
| Relative Strength Index | 55.51 |
Neuropace Forecast Models
Neuropace's time-series forecasting models are one of many Neuropace's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Neuropace's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Neuropace Debt to Cash Allocation
Many companies such as Neuropace, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Neuropace currently holds 73.34 M in liabilities with Debt to Equity (D/E) ratio of 1.08, which is about average as compared to similar companies. Neuropace has a current ratio of 9.66, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Neuropace's use of debt, we should always consider it together with its cash and equity.Neuropace Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Neuropace's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Neuropace, which in turn will lower the firm's financial flexibility.Neuropace Corporate Bonds Issued
Most Neuropace bonds can be classified according to their maturity, which is the date when Neuropace has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
About Neuropace Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Neuropace prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Neuropace shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Neuropace. By using and applying Neuropace Stock analysis, traders can create a robust methodology for identifying Neuropace entry and exit points for their positions.
NeuroPace, Inc. operates as a medical device company in the United States. The company was incorporated in 1997 and is headquartered in Mountain View, California. Neuropace operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 187 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Neuropace to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Center Now
Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios |
| All Next | Launch Module |
Complementary Tools for Neuropace Stock analysis
When running Neuropace's price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |